Open access
Sep 2026
C-peptide in MASLD – a potential driver of hepatic steatosis and fibrosis
It is proposed that C-peptide has evolved from a fibrosis biomarker to a mechanistic node and actionable target and routine integration into metabolic screening could enhance early risk stratification and monitoring of therapies modulating hyperinsulinemia.
Ahmed Mohammed Shennawy
· The Egyptian Journal of Inte... · 0 citations